Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.
This report contains market size and forecasts of Non-oncology Biopharmaceuticals in Global, including the following market information:
Global Non-oncology Biopharmaceuticals Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-oncology Biopharmaceuticals market was valued at 304180 million in 2021 and is projected to reach US$ 519380 million by 2028, at a CAGR of 7.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Biologics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-oncology Biopharmaceuticals companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-oncology Biopharmaceuticals Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-oncology Biopharmaceuticals Market Segment Percentages, by Type, 2021 (%)
Biologics
Biosimilars
Global Non-oncology Biopharmaceuticals Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-oncology Biopharmaceuticals Market Segment Percentages, by Application, 2021 (%)
Immunology
Endocrinology
Others
Global Non-oncology Biopharmaceuticals Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-oncology Biopharmaceuticals Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-oncology Biopharmaceuticals revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-oncology Biopharmaceuticals revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen